[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premature-early-ejaculation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premature-early-ejaculation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100548762","effectiveness-of-pelvic-floor-therapy-for-the-management-of-erectile-dysfunction-and-premature-ejaculation-100548762",false,"NCT06425211","Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.","Inclusion Criteria:\n\nOverall:\n\n* Men over 18 years of age\n* Erectile dysfunction or premature ejaculation for at least 6 months\n* Sexual activity with a heterosexual partner at least once a week\n* Signing of informed consent before the start of the study\n\nFor the premature ejaculation group:\n\n* Premature ejaculation according to the International Society of Sexual Medicine (ISSM) criteria\n* Premature Ejaculation Diagnosis Tool (PEDT) questionnaire score greater than 11\n\nFor the erectile dysfunction group:\n\n* Clinical diagnosis of primary erectile dysfunction\n* International Index Erectile Function - Erectile Function domain (IIEF-EF) score less than 26\n\nExclusion Criteria:\n\n* Pharmacological treatment for erectile dysfunction or premature ejaculation in the last 3 months\n* Erection Hardness Score (EHS) greater than 3 for patients with erectile dysfunction\n* History of hypogonadism or suspected hypogonadism due to Aging Males Symptoms (AMS) score greater than 36 for patients with erectile dysfunction\n* History of pelvic radiotherapy\n* Pacemaker or cardiac arrhythmia, epilepsy\n* History of spinal cord trauma or spinal surgeries.\n* Inability to attend therapies or controls\n* Illiteracy or cognitive disability that prevents you from completing the questionnaires\n* Psychiatric, psychological disorders, or cognitive deficiencies\n* Injuries in the area of application of the therapy\n* Active pelvic organ cancer","MALE","18 Years","100 Years",{"count":19,"type":20},66,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of this clinical trial is to evaluate the effectiveness of pelvic floor therapy for the management of erectile dysfunction and premature ejaculation in patients with erectile dysfunction and premature ejaculation. The main question to answer is:\n\nWhat is the effectiveness of pelvic floor therapy (electrostimulation, biofeedback, and therapeutic exercise) for the treatment of patients with erectile dysfunction and or premature ejaculation?\n\nPatients will:\n\n* Have an initial consultation of pelvic floor rehabilitation before therapy.\n* Be given pelvic floor therapy.\n* Have a secondary consultation of pelvic floor rehabilitation after therapy.\n\nThree intervention groups will be included: Group 1: Patients with premature ejaculation Group 2: Patients with erectile dysfunction Group 3: Patients with erectile dysfunction and premature ejaculation.",[26,27,28,29],"Erectile Dysfunction","Premature (Early) Ejaculation","Premature Ejaculation","Pelvic Floor; Weak","RECRUITING","2026-01-22",{"date":33,"type":34},"2026-01-23","ACTUAL",{"date":36,"type":34},"2021-10-30",{"date":38,"type":20},"2026-12",{"name":40,"class":41},"Boston Medical Group","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":67,"locationsCount":42},"100596587","phase-2-proof-of-concept-study-on-bp14979-effect-on-primary-premature-ejaculation-100596587","NCT07047404","Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation","A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of BP1.4979 in Adult Patients With Primary Premature Ejaculation","Inclusion Criteria:\n\n* Males aged 18 to 50 years old (both inclusive)\n* Diagnosis of primary (lifelong) PE according to the investigator\n* Intravaginal Ejaculatory Latency Time (IELT) estimated by the patient around one (1) minute at screening\n* Confirmation at randomization visit that at least 3 timed sexual intercourses with each IELT below 90 seconds occurred during the baseline period\n* Patient must be able to provide an informed consent and voluntarily express a willingness to participate in this study, and must sign and date an informed consent prior to any study specific procedure\n* Capability to participate in all study tests according to the investigator\n\nExclusion Criteria:\n\n* Diagnosis of acquired PE, pseudo-PE or natural variable PE\n* History of clinically significant abnormalities comprising cardiovascular (including especially prolonged QTc (\\>450 ms) and high degree (second and third) atrio-ventricular blocks)), hematological, neurological, and endocrine diseases\n* Current therapy with any treatment which may impact PE from 4 weeks prior to the screening visit\n* Current therapy with any treatment displaying dopamine D3 receptor agonist properties from 4 weeks prior to the screening visit\n* Concomitant intake of psychoactive \u002F chem-sex substances","50 Years",{"count":52,"type":20},60,[54],"PHASE2","The goal of this clinical trial is to learn if drug BP1.4979 works to treat primary premature ejaculation in adults. It will also learn about the safety of drug BP1.4979. The main questions it aims to answer are:\n\n* Does drug BP1.4979 increase the time to ejaculation during sexual intercourse?\n* Do participants have a good safety and tolerability of drug BP1.4979? Researchers will compare drug BP1.4979 to a placebo (a look-alike substance that contains no drug) to see if drug BP1.4979 works to treat primary premature ejaculation.\n\nParticipants will:\n\n* Take drug primary premature ejaculation or a placebo per requested need prior to sexual intercourses for 12 weeks\n* Visit the clinic 4 times for checkups and questionnaires completion and have 2 phone calls with the study team over a period of about 17 weeks\n* Keep a diary of the intakes of the experimental drug, ejaculation time, ejaculation control, any unusual events concerning their health and any other medication taken",[27],[58,59,60],"premature (early) ejaculation","primary premature ejaculation","Lifelong premature ejaculation","2025-10-01",{"date":63,"type":34},"2025-10-06",{"date":65,"type":34},"2025-09-15",{"date":38,"type":20},{"name":68,"class":69},"Bioprojet","OTHER"]